Tolerability of selective serotonin reuptake inhibitors: Issues relevant to the elderly

Drugs and Aging

Volumn 25, Issue 6, 2008, Pages 501-519

  Draper, Brian ^a,b   Berman, Karen ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Citalopram, therapeutic use; Elderly; Fluoxetine, therapeutic use; Fluvoxamine, therapeutic use; Paroxetine, therapeutic use; Serotonin reuptake inhibitors, therapeutic use; Sertraline, therapeutic use

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CODEINE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DIURETIC AGENT; ESCITALOPRAM; FLECAINIDE; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; LINEZOLID; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLUOXETINE; PAROXETINE; QUINIDINE; RITONAVIR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN; THEOPHYLLINE; TIMOLOL; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; UNINDEXED DRUG; WARFARIN;

ACUTE HEART INFARCTION; AGITATION; AKATHISIA; ALOPECIA; ANOREXIA; ANXIETY; ANXIETY DISORDER; BALANCE DISORDER; BRADYCARDIA; BREAST CANCER; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; COGNITIVE DEFECT; COLORECTAL CANCER; COMA; CONSTIPATION; CONTUSION; DELIRIUM; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPHONIA; DYSTONIA; ECCHYMOSIS; ELDERLY CARE; EPISTAXIS; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GALACTORRHEA; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; HYPOTENSION; INCONTINENCE; INSOMNIA; LETHARGY; MANIA; MEMORY DISORDER; MENTAL DISEASE; MYOGLOBINURIA; NAUSEA; NERVOUSNESS; NOCTURIA; PARKINSONISM; PHARMACOGENOMICS; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOSIS; PURPURA; QT PROLONGATION; RASH; REVIEW; RHABDOMYOLYSIS; SCHWARTZ BARTTER SYNDROME; SEDATION; SEIZURE; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUS BRADYCARDIA; SKIN MANIFESTATION; STROKE; SUICIDAL BEHAVIOR; SWEATING; THROMBOCYTE DYSFUNCTION; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; URINE RETENTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; PHARMACOGENETICS; SEROTONIN UPTAKE INHIBITORS;

EID: 44949099344     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825060-00004     Document Type: Review

References (152)

1. Montgomery SA. Late-life depression: rationalizing pharmacological treatment options. Gerontology 2002 Nov-Dec; 48 (6): 392-400
2. Alexopoulos GS, Schultz SK, Lebowitz BD. Late-life depression: a model for medical classification. Biol Psychiatry 2005 Aug 15; 58 (4): 283-9
3. Faculty of Psychiatry of Old Age NSW Branch, RANZCP. Consensus guidelines for assessment and management of depression in the elderly. North Sydney (NSW): NSW Department of Health, 2001
4. Unutzer J, Katon W, Callahan CM, et al. Depression treatment in a sample of 1,801 depressed older adults in primary care. J Am Geriatr Soc 2003 Apr; 51 (4): 505-14
5. Skerritt U, Evans R, Montgomery SA. Selective serotonin reuptake inhibitors in older patients: a tolerability perspective. Drugs Aging 1997 Mar; 10 (3): 209-18
6. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005 Jan 5; 97 (1): 30-9
7. Schuurmans J, Comijs H, Emmelkamp PM, et al. A randomized, controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adults. Am J Geriatr Psychiatry 2006 Mar; 14 (3): 255-63
8. Pollock B, Mulsant B, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159 (3): 460-5
9. Binder EB, Holsboer F. Pharmacogenomics and antidepressant drugs. Ann Med 2006; 38 (2): 82-94
10. Wijkstra J, Lijmer J, Balk FJ, et al. Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Br J Psychiatry 2006 May; 188: 410-5
11. Naranjo CA, Herrmann N, Mittmann N, et al. Recent advances in geriatric psychopharmacology. Drugs Aging 1995 Sep; 7 (3): 184-202
12. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32 Suppl. 1: 1-21
13. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007; 46 (4): 281-90
14. Carrasco J, Sandner C. Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract 2005; 59: 1428-34
15. Corruble E, Guelfi J. Does increasing dose improve efficacy in patients with poor antidepressant response? A review. Acta Psychiatr Scand 2000; 101: 343-8
16. Nieuwstraten C, Labiris NR, Holbrook A. Systematic overview of drug interactions with antidepressant medications. Can J Psychiatry 2006 Apr; 51 (5): 300-16
17. Mitchell PB. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Saf 1997 Dec; 17 (6): 390-406
18. Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988 Oct 8; II (8615): 850-1
19. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007 Jan 22; 167 (2): 188-94
20. Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther 2006 Apr 1; 23 (7): 937-44
21. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999 Oct 23; 319 (7217): 1106-9
22. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003 Jan 13; 163 (1): 59-64
23. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996 Oct; 57 (10): 449-54
24. Hedenmalm K, Guzey C, Dahl M-L, et al. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006 Apr; 26 (2): 192-7
25. Laugesen S, Enggaard TP, Pedersen RS, et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005 Apr; 77 (4): 312-23
26. Gillman P. A review of serotonin toxicity data: implications for the mechanism of antidepressant drug action. Biol Psychiatry 2006; 59: 1046-51
27. Boyer E, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352: 1112-20
28. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006; (1): CD003491
29. Parker G. Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scand 2002 Sep; 106 (3): 168-70
30. McManus P, Mant A, Mitchell P, et al. Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia. Aust N Z J Psychiatry 2004 Jun; 38 (6): 450-4
31. Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry 2004 Aug; 19 (8): 754-62
32. Wee R. Review: tricyclic related drugs but not classical tricyclics, are a tolerable alternative to SSRIs in older people with depression. Evid Based Ment Health 2005; 8: 22
33. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002 Sep 18; 288 (11): 1403-9
34. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004 Jul; 65 (7): 959-65
35. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med 2003 Apr 17; 348 (16): 1556-64
36. Mullins CD, Shaya FT, Meng F, et al. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 2005 May; 25 (5): 660-7
37. Macdonald L. Discontinuation reactions associated with SSRIs. Can Adv Drug React Newsl 1998; 8 (4): 3-6
38. Stahl M, Lindquist M, Pettersson M, et al. Withdrawal reactions with selective serotonin reuptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997; 53: 163-9
39. van Geffen ECG, Hugtenburg JG, Heerdink ER, et al. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Pharmacol 2005 Jun; 61 (4): 303-7
40. Kyle CJ, Petersen HE, Overo KF. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998; 8 (4): 147-53
41. Leonard BE. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs 1992; 43 Suppl. 2: 3-9; discussion 9-10
42. Gravem A, Amthor KF, Astrup C, et al. A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients. Acta Psychiatr Scand 1987 May; 75 (5): 478-86
43. Aberg-Wistedt A. The antidepressant effects of 5-HT uptake inhibitors. Br J Psychiatry Suppl 1989 Dec; (8): 32-40
44. McManis P, Talley N. Nausea and vomiting associated with SSRIs. CNS Drugs 1997 Nov; 8 (5): 394-401
45. Patel R. Clinical comparison of SSRIs in the treatment of geriatric depression: a review of the literature. Rev Clin Gerontol 2000 Nov; 10 (4): 349-73
46. Bergeron R, Blier P. Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry 1994 Jul; 151 (7): 1084-6
47. Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress Anxiety 2005; 21 (1): 26-32
48. Meijer WEE, Heerdink ER, van Eijk JT, et al. Adverse events in users of sertraline: results from an observational study in psychiatric practice in the Netherlands. Pharmacoepidemiol Drug Saf 2002 Dec; 11 (8): 655-62
49. Goldstein D, Hamilton S, Masica D, et al. Fluoxetine in medically stable, depressed geriatric patients: effect on weight. J Clin Psychopharmacol 1997 Oct; 17 (5): 365-9
50. Rigler SK, Webb MJ, Redford L, et al. Weight outcomes among antidepressant users in nursing facilities. J Am Geriatr Soc 2001 Jan; 49 (1): 49-55
51. Brymer C, Winograd CH. Fluoxetine in elderly patients: is there cause for concern? J Am Geriatr Soc 1992 Sep; 40 (9): 902-5
52. Lake MB, Birmaher B, Wassick S, et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol 2000; 10 (1): 35-8
53. Hergovich N, Aigner M, Eichler HG, et al. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000 Oct; 68 (4): 435-42
54. Layton D, Clark DW, Pearce GL, et al. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol 2001 May; 57 (2): 167-76
55. van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001 Sep 22; 323 (7314): 655-8
56. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001 Sep 1; 50 (5): 345-50
57. Tata LJ, Fortun PJ, Hubbard RB, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and nonsteroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 2005 Aug 1; 22 (3): 175-81
58. Kurdyak PA, Juurlink DN, Kopp A, et al. Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol 2005 Dec; 25 (6): 561-4
59. Dell'Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001 Jul-Aug; 24 (4): 221-7
60. Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005 Sep; 20 (9): 1161-9
61. Murphy Jr GM, Hollander SB, Rodrigues HE, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004 Nov; 61 (11): 1163-9
62. Lenze EJ, Mulsant BH, Shear MK, et al. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry 2005 Jan; 162 (1): 146-50
63. Ensrud KE, Blackwell TL, Ancoli-Israel S, et al. Use of selective serotonin reuptake inhibitors and sleep disturbances in community-dwelling older women. J Am Geriatr Soc 2006 Oct; 54 (10): 1508-15
64. Murphy Jr GM, Kremer C, Rodrigues HE, et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003 Oct; 160 (10): 1830-5
65. Schillevoort I, van Puijenbroek EP, de Boer A, et al. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol 2002 Mar; 17 (2): 75-9
66. van de Vijver DAMC, Roos RAC, Jansen PAF, et al. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol 2002 Aug; 54 (2): 168-70
67. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 1992 Aug; 53 (8): 278-82
68. Tesei S, Antonini A, Canesi M, et al. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 2000 Sep; 15 (5): 986-9
69. Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 2000 Oct 24; 55 (8): 1216-8
70. Bonvento G, MacKenzie ET, Edvinsson L. Serotonergic innervation of the cerebral vasculature: relevance to migraine and ischaemia. Brain Res Brain Res Rev 1991 Sep-Dec; 16 (3): 257-63
71. Muhonen MG, Robertson SC, Gerdes JS, et al. Effects of serotonin on cerebral circulation after middle cerebral artery occlusion. J Neurosurg 1997 Aug; 87 (2): 301-6
72. Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry 2004 Dec; 65 (12): 1642-53
73. Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002 Jan 8; 58 (1): 130-3
74. Ramasubbu R, Patten SB. Effect of depression on stroke morbidity and mortality. Can J Psychiatry 2003 May; 48 (4): 250-7
75. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999 Mar; 20 (3): 277-87
76. Beasley Jr CM, Koke SC, Nilsson ME, et al. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther 2000 Nov; 22 (11): 1319-30
77. Preda A, MacLean RW, Mazure CM, et al. Antidepressant-associated mania and psychosis resulting in psychiatric admissions. J Clin Psychiatry 2001 Jan; 62 (1): 30-3
78. Cassano GB, Puca F, Scapicchio PL, et al. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry 2002 May; 63 (5): 396-402
79. Burrows AB, Salzman C, Satlin A, et al. A randomized, placebo-controlled trial of paroxetine in nursing home residents with non-major depression. Depress Anxiety 2002; 15 (3): 102-10
80. Joss JD, Burton RM, Keller CA. Memory loss in a patient treated with fluoxetine. Ann Pharmacother 2003 Dec; 37 (12): 1800-3
81. Mowla A, Mosavinasab M, Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol 2007 Feb; 27 (1): 67-70
82. Petitpain N, Gambier N, Gillet P, et al. Dysphonia induced by selective serotonin reuptake inhibitors [letter]. South Med J 2005 Aug; 98 (8): 843
83. Cipriani A, Barbui C, Geddes JR. Suicide, depression, and antidepressants. BMJ 2005 Feb 19; 330 (7488): 373-4
84. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials [published erratum appears in BMJ 2005 Mar 19; 330 (7492): 653]. BMJ 2005 Feb 19; 330 (7488): 396-402
85. Didham RC, McConnell DW, Blair HJ, et al. Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication. Br J Clin Pharmacol 2005 Nov; 60 (5): 519-25
86. Friedman R, Leon A. Expanding the black box: depression, antidepressants, and the risk of suicide. N Engl J Med 2007; 356: 2343-6
87. Koski A, Vuori E, Ojanpera I. Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data. Int J Legal Med 2005 Nov; 119 (6): 344-8
88. Isacsson G. Suicide prevention: a medical breakthrough? Acta Psychiatr Scand 2000; 102: 113-7
89. Isacsson G, Rich CL. Antidepressant drug use and suicide prevention. Int Rev Psychiatry 2005; 1 (17): 153-62
90. Hall W, Mant A, Mitchell P, et al. Association between antidepressant prescribing and suicide in Australia; 1991-2000: trend analysis. BMJ 2003; 326 (7397): 1008-112
91. Draper B. Antidepressant prescribing and suicide: associations attribute possible causality inappropriately [letter]. BMJ 2003; 327 (7409): 288
92. Juurlink DN, Mamdani MM, Kopp A, et al. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 2006 May; 163 (5): 813-21
93. Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2002 Apr 28; 163 (8): 949-57
94. Arfken CL, Wilson JG, Aronson SM. Retrospective review of selective serotonin reuptake inhibitors and falling in older nursing home residents. Int Psychogeriatr 2001 Mar; 13 (1): 85-91
95. Kallin K, Gustafson Y, Sandman P-O, et al. Drugs and falls in older people in geriatric care settings. Aging Clin Exp Res 2004 Aug; 16 (4): 270-6
96. Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998 May 2; 351 (9112): 1303-7
97. Hubbard R, Farrington P, Smith C, et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003 Jul 1; 158 (1): 77-84
98. French DD, Campbell R, Spehar A, et al. Outpatient medications and hip fractures in the US: a national veterans study. Drugs Aging 2005; 22 (10): 877-85
99. Pacher P, Ungvari Z. Selective serotonin-reuptake inhibitor antidepressants increase the risk of falls and hip fractures in elderly people by inhibiting cardiovascular ion channels. Med Hypotheses 2001 Oct; 57 (4): 469-71
100. Rodriguez de la Torre B, Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonic reuptake inhibitors in depressed patients. Ther Drug Monit 2001 Aug; 23 (4): 435-40
101. Cherin P, Colvez A, Deville de Periere G, et al. Risk of syncope in the elderly and consumption of drugs: a case-control study. J Clin Epidemiol 1997 Mar; 50 (3): 313-20
102. Le Couteur DG, Fisher AA, Davis MW, et al. Postprandial systolic blood pressure responses of older people in residential care: association with risk of falling. Gerontology 2003 Jul-Aug; 49 (4): 260-4
103. Jensen J, Lundin-Olsson L, Nyberg L, et al. Falls among frail older people in residential care. Scand J Public Health 2002; 30 (1): 54-61
104. Mamo DC, Pollock BG, Mulsant B, et al. Effects of nortriptyline and paroxetine on postural sway in depressed elderly patients. Am J Geriatr Psychiatry 2002 Mar-Apr; 10 (2): 199-205
105. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother 2006 Sep; 40 (9): 1618-22
106. Kirby D, Ames D. Hyponatraemia and selective serotonin reuptake inhibitors in elderly patients. Int J Geriatr Psychiatry 2001 May; 16 (5): 484-93
107. Stedman CAM, Begg EJ, Kennedy MA, et al. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Hum Psychopharmacol 2002 Jun; 17 (4): 187-90
108. Odeh M, Seligmann H, Oliven A. Severe life-threatening hyponatremia during paroxetine therapy. J Clin Pharmacol 1999 Dec; 39 (12): 1290-1
109. Degner D, Grohmann R, Kropp S, et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004 Mar; 37 Suppl. 1: S39-45
110. Kirchner V, Silver LE, Kelly CA. Selective serotonin reuptake inhibitors and hyponatraemia: review and proposed mechanisms in the elderly. J Psychopharmacol 1998; 12 (4): 396-400
111. Kirby D, Harrigan S, Ames D. Hyponatraemia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. Int J Geriatr Psychiatry 2002 Mar; 17 (3): 231-7
112. Arinzon ZH, Lehman YA, Fidelman ZG, et al. Delayed recurrent SIADH associated with SSRIs. Ann Pharmacother 2002 Jul-Aug; 36 (7-8): 1175-7
113. Pollak PT, Mukherjee SD, Fraser AD. Sertraline-induced hypoglycemia. Ann Pharmacother 2001 Nov; 35 (11): 1371-4
114. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005 Nov; 84 (6): 377-85
115. Bonin B, Vandel P, Sechter D, et al. Paroxetine and galactorrhea. Pharmacopsychiatry 1997 Jul; 30 (4): 133-4
116. Gonzalez E, Minguez L, Sanguino RM. Galactorrhea after paroxetine treatment [letter]. Pharmacopsychiatry 2000 May; 33 (3): 118
117. Davenport E, Velamoor R. A case of paroxetine-induced galactorrhea. Can J Psychiatry 2002 Nov; 47 (9): 890-1
118. Brucculeri M, Kaplan J, Lande L. Reversal of citalopram-induced junctional bradycardia with intravenous sodium bicarbonate. Pharmacotherapy 2005 Jan; 25 (1): 119-22
119. Isbister GK, Bowe SJ, Dawson A, et al. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004; 42 (3): 277-85
120. Tata LJ, West J, Smith C, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart 2005 Apr; 91 (4): 465-71
121. Xiong GL, Jiang W, Clare R, et al. Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. Am J Cardiol 2006 Jul 1; 98 (1): 42-7
122. Schlienger RG, Fischer LM, Jick H, et al. Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf 2004; 27 (14): 1157-65
123. Serebruany VL, Glassman AH, Malinin AI, et al. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail 2003 Aug; 5 (4): 517-21
124. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003 Jul 8; 108 (1): 32-6
125. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001 Oct 16; 104 (16): 1894-8
126. MacDonald TM, McMahon AD, Reid IC, et al. Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. BMJ 1996 Oct 5; 313 (7061): 860-1
127. Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol 2001 Aug; 52 (2): 179-84
128. Monster TBM, Johnsen SP, Olsen ML, et al. Antidepressants and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. Am J Med 2004 Nov 15; 117 (10): 732-7
129. Votolato NA, Stern S, Caputo RM. Serotonergic antidepressants and urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2000 Dec; 11 (6): 386-8
130. Movig KLL, Leufkens HGM, Belitser SV, et al. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf 2002 Jun; 11 (4): 271-9
131. Asplund R, Johansson S, Henriksson S, et al. Nocturia, depression and antidepressant medication. BJU Int 2005 Apr; 95 (6): 820-3
132. Steingart A, Cotterchio M, Kreiger N, et al. Antidepressant medication use and breast cancer risk: a case-control study. Int J Epidemiol 2003 Dec; 32 (6): 961-6
133. Cotterchio M, Kreiger N, Darlington G, et al. Antidepressant medication use and breast cancer risk. Am J Epidemiol 2000 May 15; 151 (10): 951-7
134. Kelly JP, Rosenberg L, Palmer JR, et al. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol 1999 Oct 15; 150 (8): 861-8
135. Chien C, Li CI, Heckbert SR, et al. Antidepressant use and breast cancer risk. Breast Cancer Res Treat 2006 Jan; 95 (2): 131-40
136. Wang PS, Walker AM, Tsuang MT, et al. Antidepressant use and the risk of breast cancer: a non-association. J Clin Epidemiol 2001 Jul; 54 (7): 728-34
137. Barkla DH, Tutton PJ. Influence of histamine and serotonin antagonists on the growth of xenografted human colorectal tumors. J Natl Cancer Inst 1981 Dec; 67 (6): 1207-11
138. Xu W, Tamim H, Shapiro S, et al. Use of antidepressants and risk of colorectal cancer: a nested case-control study. Lancet Oncol 2006 Apr; 7 (4): 301-8
139. Mercke Y, Sheng H, Khan T, et al. Hair loss in psychopharmacology. Ann Clin Psychiatry 2000 Mar; 12 (1): 35-42
140. Hedenmalm K, Sundstrom A, Spigset O. Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs). Pharmacoepidemiol Drug Saf 2006 Oct; 15 (10): 719-25
141. Gulec AT, Tanriverdi N, Duru C, et al. The role of psychological factors in alopecia areata and the impact of the disease on the quality of life. Int J Dermatol 2004 May; 43 (5): 352-6
142. Nebert DW, Dieter MZ. The evolution of drug metabolism. Pharmacology 2000 Sep; 61 (3): 124-35
143. Bertilsson L, Dahl M-L, Dalen P, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002 Feb; 53 (2): 111-22
144. Feng Y, Pollock BG, Ferrell RE, et al. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol 2006 May; 61 (5): 558-69
145. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages [erratum appears in Acta Psychiatr Scand 2001 Dec; 104 (6): 475]. Acta Psychiatr Scand 2001 Sep; 104 (3): 173-92
146. Wedlund PJ, de Leon J. Cytochrome P450 2D6 and antidepressant toxicity and response: what is the evidence? Clin Pharmacol Ther 2004 May; 75 (5): 373-5
147. Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants: a pilot study. Clin Pharmacol Ther 2004 May; 75 (5): 386-93
148. Zourkova A, Hadasova E. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurrence of adverse effects. Gen Physiol Biophys 2003 Mar; 22 (1): 103-13
149. Roberts RL, Mulder RT, Joyce PR, et al. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline [see comment]. Hum Psychopharmacol 2004 Jan; 19 (1): 17-23
150. Solai LK, Pollock BG, Mulsant BH, et al. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. J Clin Psychopharmacol 2002 Oct; 22 (5): 481-6
151. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000 Nov; 23 (5): 587-90
152. Perlis RH, Mischoulon D, Smoller JW, et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003 Nov 1; 54 (9): 879-83